Sign in

CIK 0001501697 · Non-accelerated filer<br>Smaller reporting company

X4 Pharmaceuticals, Inc

Sign in to watch
Ticker
XFOR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
273181608
Phone
857-529-8300
Business address
61 NORTH BEACON STREET, 4TH FLOOR, BOSTON, MA, 02134
Former names
Arsanis, Inc.
  1. 4 Open-market sale Chief Financial Officer sold 52,500 shares at $0.88 ($46,347)
  2. 4 Open-market sale Chief Operating Officer sold 15,409 shares at $0.88 ($13,591)
  3. 4/A Derivatives Options or other derivatives
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 4 Derivatives Options or other derivatives
  8. 4 Derivatives Options or other derivatives
  9. 4 Derivatives Options or other derivatives
  10. 4 Open-market sale Chief Operating Officer sold 3,683 shares at $1.01 ($3,709)
  11. 4 Open-market sale Chief Scientific Officer sold 787 shares at $1.01 ($793)
  12. 4 Open-market sale President and CEO sold 21,695 shares at $1.01 ($21,892)
  13. 4 Open-market sale Chief Financial Officer sold 27,721 shares at $1.01 ($27,973)
  14. 4 Planned sale President and CEO sold 239,437 shares at an average $0.76 ($181,573)
  15. 4 Planned sale Chief Financial Officer sold 230,645 shares at $0.73 ($168,371)
  16. 4 Planned sale Chief Operating Officer sold 67,695 shares at $0.73 ($49,417)
  17. 4 Planned sale Chief Commercial Officer sold 10,257 shares at $0.73 ($7,488)
  18. 4 Planned sale Chief Scientific Officer sold 67,695 shares at $0.73 ($49,417)
  19. 4 Grant or award Chief Financial Officer acquired 230,645 shares (grant or award)
  20. 4 Grant or award Chief Commercial Officer acquired 34,947 shares (grant or award)

Page 4 of 17 · 329 filings